224 related articles for article (PubMed ID: 27129162)
21. Burn injury induces the expression of cystine/glutamate transporter (x(c)(-)) in mouse T cells.
D'Elia M; Patenaude J; Dupras C; Bernier J
Immunol Lett; 2009 Aug; 125(2):137-44. PubMed ID: 19576933
[TBL] [Abstract][Full Text] [Related]
22. Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma.
Guo W; Zhao Y; Zhang Z; Tan N; Zhao F; Ge C; Liang L; Jia D; Chen T; Yao M; Li J; He X
Cancer Lett; 2011 Dec; 312(1):55-61. PubMed ID: 21906871
[TBL] [Abstract][Full Text] [Related]
23. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.
Otsuki Y; Yamasaki J; Suina K; Okazaki S; Koike N; Saya H; Nagano O
Cancer Sci; 2020 Jan; 111(1):127-136. PubMed ID: 31692172
[TBL] [Abstract][Full Text] [Related]
24. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
[TBL] [Abstract][Full Text] [Related]
25. Administering xCT Inhibitors Based on Circadian Clock Improves Antitumor Effects.
Okazaki F; Matsunaga N; Hamamura K; Suzuki K; Nakao T; Okazaki H; Kutsukake M; Fukumori S; Tsuji Y; To H
Cancer Res; 2017 Dec; 77(23):6603-6613. PubMed ID: 29038345
[TBL] [Abstract][Full Text] [Related]
26. Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity.
Linher-Melville K; Nashed MG; Ungard RG; Haftchenary S; Rosa DA; Gunning PT; Singh G
PLoS One; 2016; 11(8):e0161202. PubMed ID: 27513743
[TBL] [Abstract][Full Text] [Related]
27. Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice.
Miyazaki I; Murakami S; Torigoe N; Kitamura Y; Asanuma M
J Neurochem; 2016 Jan; 136(1):194-204. PubMed ID: 26485447
[TBL] [Abstract][Full Text] [Related]
28. System x
Kitagawa Y; Nakaso K; Horikoshi Y; Morimoto M; Omotani T; Otsuki A; Inagaki Y; Sato H; Matsura T
Sci Rep; 2019 May; 9(1):7562. PubMed ID: 31101857
[TBL] [Abstract][Full Text] [Related]
29. Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells.
Okamoto K; Saito Y; Ueda H; Narumi K; Furugen A; Kobayashi M
Biopharm Drug Dispos; 2021 Sep; 42(8):389-392. PubMed ID: 34287957
[TBL] [Abstract][Full Text] [Related]
30. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.
Guan J; Lo M; Dockery P; Mahon S; Karp CM; Buckley AR; Lam S; Gout PW; Wang YZ
Cancer Chemother Pharmacol; 2009 Aug; 64(3):463-72. PubMed ID: 19104813
[TBL] [Abstract][Full Text] [Related]
31. ASK1-p38 MAPK-p47phox activation is essential for inflammatory responses during tuberculosis via TLR2-ROS signalling.
Yang CS; Shin DM; Lee HM; Son JW; Lee SJ; Akira S; Gougerot-Pocidalo MA; El-Benna J; Ichijo H; Jo EK
Cell Microbiol; 2008 Mar; 10(3):741-54. PubMed ID: 18028450
[TBL] [Abstract][Full Text] [Related]
32. Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models.
Ruiu R; Cossu C; Iacoviello A; Conti L; Bolli E; Ponzone L; Magri J; Rumandla A; Calautti E; Cavallo F
J Exp Clin Cancer Res; 2023 Sep; 42(1):254. PubMed ID: 37770957
[TBL] [Abstract][Full Text] [Related]
33. The viability of primary hepatocytes is maintained under a low cysteine-glutathione redox state with a marked elevation in ophthalmic acid production.
Lee J; Kang ES; Kobayashi S; Homma T; Sato H; Seo HG; Fujii J
Exp Cell Res; 2017 Dec; 361(1):178-191. PubMed ID: 29079265
[TBL] [Abstract][Full Text] [Related]
34. Differential regulation of cell proliferation in neurogenic zones in mice lacking cystine transport by xCT.
Liu RR; Brown CE; Murphy TH
Biochem Biophys Res Commun; 2007 Dec; 364(3):528-33. PubMed ID: 17963724
[TBL] [Abstract][Full Text] [Related]
35. Decreased reproductive performance in xCT-knockout male mice.
Hamashima S; Homma T; Kobayashi S; Ishii N; Kurahashi T; Watanabe R; Kimura N; Sato H; Fujii J
Free Radic Res; 2017 Oct; 51(9-10):851-860. PubMed ID: 28974116
[TBL] [Abstract][Full Text] [Related]
36. Behavioral characterization of system xc- mutant mice.
McCullagh EA; Featherstone DE
Behav Brain Res; 2014 May; 265():1-11. PubMed ID: 24548853
[TBL] [Abstract][Full Text] [Related]
37. System xC- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice.
Mesci P; Zaïdi S; Lobsiger CS; Millecamps S; Escartin C; Seilhean D; Sato H; Mallat M; Boillée S
Brain; 2015 Jan; 138(Pt 1):53-68. PubMed ID: 25384799
[TBL] [Abstract][Full Text] [Related]
38. MPTP-induced parkinsonism in mice alters striatal and nigral xCT expression but is unaffected by the genetic loss of xCT.
Bentea E; Sconce MD; Churchill MJ; Van Liefferinge J; Sato H; Meshul CK; Massie A
Neurosci Lett; 2015 Apr; 593():1-6. PubMed ID: 25766755
[TBL] [Abstract][Full Text] [Related]
39. Induction of cystine-glutamate transporter xc- by human immunodeficiency virus type 1 transactivator protein tat in retinal pigment epithelium.
Bridges CC; Hu H; Miyauchi S; Siddaramappa UN; Ganapathy ME; Ignatowicz L; Maddox DM; Smith SB; Ganapathy V
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2906-14. PubMed ID: 15326101
[TBL] [Abstract][Full Text] [Related]
40. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death.
Banjac A; Perisic T; Sato H; Seiler A; Bannai S; Weiss N; Kölle P; Tschoep K; Issels RD; Daniel PT; Conrad M; Bornkamm GW
Oncogene; 2008 Mar; 27(11):1618-28. PubMed ID: 17828297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
